Maarten Meulenbelt revisits the European Commission’s final report into competition in the pharmaceutical sector and explains why it is unsatisfactory.
When the preliminary report on competition in the pharmaceutical sector was published in November 2008 by the European Commission’s Directorate-General for Competition (DG COMP)1, it was accompanied by a strongly worded press release2...
Please login to read the full article.
